Introduction
============

Antimicrobial resistance occurs when bacteria are no longer susceptible to the drugs used for treatment.[@R1] Increasingly, there are fewer antimicrobial drugs available to effectively treat common as well as life-threatening infections. Annual deaths from untreatable infections may rise from estimated 700 000 in 2015 to 10 million by 2050 if antimicrobial resistance is not controlled.[@R2] Common procedures such as surgery or cancer chemotherapy may become too dangerous to perform without effective antibiotics.

Extended-spectrum β-lactamases are enzymes that cause resistance to some of the most commonly used antibiotics,[@R3] including all penicillins, cephalosporins and monobactams.[@R3] Fortunately these enzymes have yet to confer resistance to carbapenems, making these drugs valuable for serious extended-spectrum β-lactamase-producing bacterial infections.[@R4] However, there have been recent outbreaks of extended-spectrum β-lactamase-producing *Klebsiella* spp. with carbapenem resistance, resulting in extremely high rates of mortality.[@R5]^,^[@R6] Within the already limited selection of antibiotics available to treat these infections, fewer are approved for use in children.[@R7] Children are particularly vulnerable to bacterial infections compared with young adults, due to their immature immune systems.[@R8]^,^[@R9]

The World Health Organization (WHO) South-East Asia and Western Pacific Regions have over 4.3 billion of the world's population of 7.7 billion, including two of the most populous countries with heavy consumption of antibiotics: China and India.[@R10] Research suggests these regions have high antimicrobial resistance rates to extended-spectrum β-lactamase-producing bacteria in the paediatric population.[@R11] Poor-quality antibiotics and unsupervised use are common across the Regions. The available studies provide an overall impression of the prevalence of antibiotic resistance in the Regions, but better evidence is needed about the risk factors and outcomes for children with these infections. We therefore aimed to make a systematic review and meta-analysis of the risk factors and outcomes of infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in children and young adults in the South-East Asia and the Western Pacific. We also mapped the prevalence of extended-spectrum β-lactamase-associated infections in countries and areas of the Regions using the available surveillance data.

Methods
=======

Meta-analysis
-------------

We conducted the meta-analysis in accordance with the *Cochrane handbook for systematic reviews of interventions*.[@R12] All procedures followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@R13] The study was registered in the PROSPERO International prospective register of systematic reviews (CRD42017069701).

### Search strategy

We made a comprehensive search, without language limitation, of online databases for articles published from 1 January 1940 to 30 June 2018 ([Box 1](#B1){ref-type="boxed-text"}). Two researchers independently conducted the search and screened the titles, abstracts and full texts of the papers. We used a standardized, piloted data collection form to determine whether papers were appropriate for inclusion. The researchers applied the Newcastle--Ottawa scale to assess risk of bias in non-randomized studies.[@R14] Studies scoring ≥ 5 and ≤ 8 were designated low risk of bias, ≥ 3 and ≤ 4 as moderate and ≤ 2 as high. We incorporated the quality assessment results into our sensitivity analysis using the Meta-analyses Of Observational Studies in Epidemiology checklist. Discrepancies at any stage of the analysis were resolved by consensus of the researchers.

###### Search strategy used in the systemic review of extended-spectrum β-lactamase-associated infection among children and young adults in South-East Asia and Western Pacific countries

We searched online databases (Embase®, MEDLINE®, Cochrane Library, Web of Science, Scopus, OvidSP®, EBSCO), electronic abstract databases and references in published articles. For the prevalence study we also searched the grey literature, including the websites of the World Health Organization and the United States Centers for Disease Control, surveillance systems related to antimicrobial resistance, dissertations, conference reports and country reports. When more information about studies was needed we contacted authors or website administrators.

We used the following keywords:

extended-spectrum beta-lactamase OR extended-spectrum beta-lactamase OR ESBL\* OR ESBLs OR ESBL-producing\*

AND paediatric OR pediatric OR juvenile OR child OR children OR adolescence OR infant OR neonat\* OR neonatal OR newborn OR nursery

AND Asia OR Asia Pacific OR South Asia OR The Western Pacific OR South-East Asia OR Australia OR Bangladesh OR Bhutan OR Brunei Darussalam OR Cambodia OR China OR Cook Islands OR Democratic People\'s Republic of Korea OR Fiji OR India OR Indonesia OR Japan OR Kiribati OR Lao People\'s Democratic Republic OR Malaysia OR Maldives OR Marshall Islands OR Federated States of Micronesia (Federated States of) OR Mongolia OR Myanmar OR Nauru OR Nepal OR New Zealand OR Niue OR Palau OR Papua New Guinea OR Philippines OR Republic of Korea OR Samoa OR Singapore OR Solomon Islands OR Sri Lanka OR Thailand OR Timor-Leste OR Tonga OR Tuvalu OR Vanuatu OR VietNam

### Selection criteria

We included cohort, case--control and observational or cross-sectional studies. We defined the target population as children aged from birth to 21 years, according the American Academy of Paediatrics guidelines.[@R15] We included studies that were conducted in the WHO South-East Asia and Western Pacific Regions and that recorded both positive and negative results of testing for extended-spectrum β-lactamase-producing bacteria.

### Outcome measures

The principal outcome measure was patients' infection status, defined by whether specimens obtained tested positive or negative for infection with extended-spectrum β-lactamase-producing bacteria. We analysed infection status by risk sub-groups: medical history in the 3 months before the infection (hospital stay, intensive care unit admission, surgery), exposure to invasive life support, antibiotic therapy and co-morbidities or underlying conditions. Other outcomes recorded were: hospital length of stay, mortality, persistent bacteraemia, antibiotic residence and duration of fever after antibiotic therapy.

### Data synthesis and analysis

For the meta-analysis we pooled the data on number of isolates (four studies) or patients with isolates (37 studies) using a Mantel--Haenszel random-effects model to determine the risk of infection with extended-spectrum β-lactamase-producing bacteria.[@R16] We calculated pooled odds ratio (OR) and 95% confidence intervals (CI) for dichotomous outcomes and weighted mean difference and 95% CI for continuous outcomes. All tests were two-tailed and *P* \< 0.05 was considered statistically significant. If studies provided median and interquartile range, we made estimates of the mean and standardized deviation (SD).[@R17]

We assessed the heterogeneity of the studies using the *I^2^* statistic, which evaluates the consistency of study results. The cut-off for defining heterogeneity was *I^2^* \> 50%.[@R18] Our sensitivity analyses were based on sample size on the overall summary estimates.[@R19] We evaluated whether this restricted analysis affected the magnitude, direction and statistical significance of the overall summary estimate. Additional sensitivity analyses assessed the different types of study designs, settings and risk of bias.

We carried out meta-regression to explore each potential factor contributing to heterogeneity between studies, such as study location, design, duration and setting, and patients' age and diagnosis, for all included studies reporting mortality and persistent bacteraemia. We used funnel plots with Egger regression test to assess publication bias (*P* \< 0.1).

All statistical analyses were performed with R software, version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria), using the Meta and Metafor meta-analysis packages.

Prevalence study
----------------

We obtained data on the prevalence of extended-spectrum β-lactamase-associated infection from the same studies included in the meta-analysis. We also made a search for other data sources in the published and grey literature ([Box 1](#B1){ref-type="boxed-text"}). We included data on children (ages 0--21 years), where available, and all age groups, if data for these ages were unavailable. We calculated percentage prevalence by the number of people or isolates testing positive for extended-spectrum β-lactamases out of the total population or isolates tested. For case--control studies, the overall prevalence rate was extracted instead. Numbers of cases and samples were extracted if stated by the source. Where population maps were provided in the source material, the average of the range were extracted as the prevalence in the country. We pooled the prevalence data by calculating the mean of the extracted data from all sources for each country.

Results
=======

Meta-analysis
-------------

### Study selection and characteristics

The database search yielded 6665 articles. We removed 1089 duplicates and excluded a further 3046 studies after screening titles and abstracts. After assessing the full text of 577 studies, we excluded 537. Screening of reference lists and conference abstracts yielded no additional studies. In total, 40 studies were included in the meta-analysis ([Fig. 1](#F1){ref-type="fig"}). Three studies were reported in Chinese language, one study each in Korean and French, and the remaining 35 were in English.
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Overall, the 40 studies reported 46 960 bacterial isolates from 17 829 children providing samples. We pooled data from 2411 samples testing positive and 2874 testing negative for extended-spectrum β-lactamase-producing bacteria over the study period up to June 2018. The most common method of detection of bacterial phenotypes was agar disk diffusion in 32 studies. The study designs were 11 retrospective cohort studies, 14 prospective cohort studies, six observational studies, two cross-sectional studies and seven case--control studies. We found studies from 11 different countries and areas: Taiwan, China; India; Indonesia; Japan; Malaysia; Republic of Korea; Singapore; Sri Lanka; Thailand; and Viet Nam. In 15 studies the focus was specifically on neonates (\< 28 days old), 15 studies were of age groups 0--21 years (excluding neonates), seven studies were of age 0--5 years (excluding neonates) and three studies did not specify the ages ([Table 1](#T1){ref-type="table"}; available at: <http://www.who.int/bulletin/volumes/96/7/18-225698>).

###### Characteristics of 40 studies included in the meta-analysis of extended-spectrum β-lactamase-associated infection among children and young adults in South-East Asia and Western Pacific countries, 2002--2018

  Author                                 Country or area       Study dates            Study design      Study duration     Study setting          Diagnosis                           Specimen site   Sample ages         No. of children   No. of samples   Prevalence of ESBL infection, %   No. of isolates or cultures   Bacterial species   ESBL detection method                                                                                                        Guidelines used                            
  -------------------------------------- --------------------- ---------------------- ----------------- ------------------ ---------------------- ----------------------------------- --------------- ------------------- ----------------- ---------------- --------------------------------- ----------------------------- ------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ --------------------------------------
  Kim et al., 2002[@R20]                 Republic of Korea     Nov 1993--Dec 1998     Cohort            5 years            Community              Urinary tract infection             Urine           0--17 years         142               49               93                                17                            157                 *Escherichia coli*, *Klebsiella pneumoniae*                                                                                  Double disk diffusion                      NCCLS, 2002
  Jain et al., 2003[@R21]                India                 1 year                 Cohort            1 year             Hospital               Sepsis                              Blood           Neonates            728               165              36                                79                            400                 *E. coli*, *K. pneumoniae, Enterobacter* spp.                                                                                Double disk synergy test                   CLSI, 2000 & NCCLS, date NS
  Boo et al., 2005[@R22]                 Malaysia              1996--Oct 2002         Case--control     7 years            Hospital               Sepsis                              Various         Neonates            350               80               80                                22                            369                 *K. pneumoniae*, *Enterobacter* spp.                                                                                         Double disk diffusion                      Ministry of Health of Malaysia, 2001
  Chiu et al., 2005[@R23]                Taiwan, China         Jan 2001--Dec 2001     Cohort            1 year             Hospital               Nosocomial infection                Various         Neonates            76                34               42                                44                            76                  *E. coli*, *K. pneumoniae,* KS                                                                                               Double disk diffusion                      NCCLS, 2001
  Huang et al., 2007[@R24]               China                 Jan 2000--Dec 2002     Cohort            3 years            Hospital               Nosocomial infection                Various         Neonates            39                22               17                                56                            2358                *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      NCCLS, 2000
  Jain & Mondal, 2007[@R25]^,b^          India                 Jan 2004--Dec 2005     Cohort            2 years            Hospital               Sepsis                              Blood           Neonates            100               58               42                                58                            2995                *K. pneumoniae, Enterobacter* spp.                                                                                           Double disk diffusion                      NCCLS, 2003
  Kuo et al., 2007[@R26]                 Taiwan, China         Jan 2000--Oct 2005     Case--control     5 years 9 months   Hospital               Various                             Various         Birth to NS         108               54               54                                28                            274                 *K. pneumoniae*                                                                                                              Double disk diffusion                      NCCLS, 2001
  Lee et al., 2007[@R27]                 Republic of Korea     Jan 1999--Dec 2005     Cohort            7 years            Hospital               Various                             Various         NS                  228               35               54                                29                            252                 *E. coli*, *K. pneumoniae*                                                                                                   Double disk synergy test, Vitek-GNI card   CLSI, 2005
  Sehgal et al., 2007[@R28]              India                 April 2002--May 2003   Cohort            1 year             Hospital               Sepsis                              Blood           Neonates            75                38               25                                61                            75                  Multiple species^a^                                                                                                          Double disk diffusion                      NCCLS, 2002
  Bhattacharjee et al., 2008[@R29]^,b^   India                 14 months              Cohort            1 year 2 months    Hospital               Sepsis                              Blood           Neonates            243               26               58                                32                            243                 Multiple species^a^                                                                                                          Double disk diffusion                      CLSI, 2008
  Anandan et al., 2009[@R30]^,b^         India                 Jan 2003--Dec 2007     Cohort            5 years            Hospital               Sepsis                              Blood           Neonates            94                68               26                                72                            8330                *E. coli*, *K. pneumoniae*                                                                                                   Not specify                                CLSI, 2008
  Kim et al., 2009[@R31]                 Republic of Korea     Jan 2004--Apr 2009     Cohort            5 years 2 months   Community              Urinary tract infection             Urine           Children            854               32               83                                17                            681                 *E. coli*, *K. pneumoniae*                                                                                                   Vitek 2 system                             CLSI, date NS
  Shakil et al., 2010[@R32]              India                 Jan 2006--Feb 2007     Cohort            1 years            Hospital               Various                             Various         Neonates            238               104              107                               44                            469                 *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, date NS
  Gaurav et al., 2011[@R33]              India                 May 2007--Apr 2008     Case--control     1 year             Hospital               Sepsis                              Blood           Neonates            344               50               52                                36                            5116                *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, date NS
  Liu et al., 2011[@R34]                 China                 Feb 2009--Jan 2011     Cohort            2 years            Hospital               Lower respiratory tract infection   Sputum          \< 3 years          242               94               148                               39                            242                 Multiple species^a^                                                                                                          Double disk synergy test                   CLSI, date NS
  Wei et al., 2011[@R35]                 China                 Jan 2009--Dec 2009     Observational     1 year             Hospital               Lower respiratory tract infection   Sputum          \< 1 year           272               144              128                               53                            1380                Multiple species^a^                                                                                                          Double disk synergy test                   CLSI, 2009
  Minami et al., 2012[@R36]              Japan                 July 2011 (1 day)      Cross-sectional   1 day              Hospital               Various                             Rectal          ≤ 12 years          50                44               6                                 12                            62                  Multiple species^a^                                                                                                          Double disk synergy test                   CLSI, 2008
  Zheng et al., 2012[@R37]               China                 2002--2008             Cohort            6 years            Hospital               Haematological malignancy           Blood           \< 16 years         109               19               38                                52                            3264                *E. coli*, *K. pneumoniae*                                                                                                   Vitek 60 system                            NCCLS, date NS
  Vijayakanthi et al., 2013[@R38]        India                 Dec 2009--Nov 2010     Cohort            1 year             Hospital               Sepsis                              Various         Neonates            150               8                39                                17                            150                 Multiple species^a^                                                                                                          Double disk diffusion                      CLSI, date NS
  Fan et al. 2014[@R39]                  Taiwan, China         2002--2006             Case--control     4 years            Community              Urinary tract infection             Urine           \< 15 years         312               104              208                               33                            6467                *E. coli*                                                                                                                    Double disk diffusion                      CLSI, 2007
  Themphachana et al., 2014[@R40]        Thailand              Feb--Sep 2013          Observational     8 months           Hospital               Urinary tract infection             Urine           \< 21 years         166               82               83                                26                            166                 *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, 2012
  Young et al., 2014[@R41]               Singapore             Nov 2006--Feb 2007     Observational     3 months           Community              Various                             Various         \< 21 years         1006              69               124                               4                             1006                ESBL-producing Enterobacteriaceae, methicillin-resistant *Staphylococcus aureus*; vancomycin-resistant *Enterococcus* spp.   Double disk diffusion                      CLSI, 2007
  Zuo et al., 2014[@R42]                 China                 Jan--Dec 2013          Observational     1 year             Hospital               Lower respiratory tract infection   Sputum          1‒3 months          622               93               94                                79                            379                 *E. coli*, *K. pneumoniae*                                                                                                   Kirby-Bauer disk diffusion                 CLSI, 2012
  Duong et al., 2015[@R43]               Viet Nam              Jul 2011--Nov 2012     Cohort            1 year 4 months    Hospital               Urinary tract infection             Various         3 months‒15 years   216               22               17                                52                            143                 *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, 2007
  Han et al., 2015[@R17]^,c^             Republic of Korea     Apr 2009--Mar 2013     Cohort            4 years            Hospital               Neutropoenia (febrile)              Blood           \< 20 years         61                21               40                                34                            61                  *E. coli*, *K. pneumoniae*                                                                                                   Vitek 2 system                             NS
  Han et al., 2015[@R44]^,d^             Republic of Korea     Jan 2010--Dec 2014     Cohort            4 years            Hospital               Urinary tract infection             Urine           \< 18 years         205               22               189                               10                            211                 *E. coli*, *K. pneumoniae*                                                                                                   Vitek 2 system                             NS
  Nisha et al., 2015[@R45]               India                 Nov 2012--Jan 2015     Cohort            3 years            Community              Urinary tract infection             Urine           ≤ 18 years          385               159              226                               41                            385                 *E. coli*                                                                                                                    Kirby-Bauer disk diffusion                 CLSI, date NS
  Agarwal et al., 2016 [@R46]^,b^        India                 2009--2012             Cohort            4 years            Hospital               Diarrhoea                           Stool           Young children      6339              23               98                                19                            6339                *E. coli*, *K. pneumoniae*                                                                                                   Vitek 2 system                             CLSI, date NS
  Amornchaicharoensuk, 2016[@R47]        Thailand              Jan 2010--Dec 2014     Cohort            5 years            Hospital               Urinary tract infection             Urine           0--15 years         117               19               69                                16                            117                 *E. coli*, *K. pneumoniae*                                                                                                   Hospital laboratory                        CLSI, date NS
  Sharma et al., 2016[@R48]              India                 Jan 2013--Aug 2014     Observational     1 year 7 months    Hospital               Sepsis                              Blood           Neonates            1449              101              66                                61                            1449                Multiple species^a^                                                                                                          Double disk synergy test                   NCCLS, date NS
  Tsai et al., 2016[@R49]                Taiwan, China         Jan 2001--Dec 2012     Case--control     12 years           Hospital               Bacteraemia                         Blood           Neonates            350               77               316                               14                            542                 Multiple species^a^                                                                                                          Double disk synergy test                   CLSI, 2012
  Chen et al., 2017[@R50]                Taiwan, China         Jan 2004--Jul 2015     Cross-sectional   11 years           Hospital               Bacteraemia                         Blood           Neonates            27                5                22                                19                            27                  *E. coli*                                                                                                                    Not specify                                NS
  He et al., 2017[@R51]                  China                 Mar 2011--Jun 2016     Cohort            4 years 3 months   Hospital               Lower respiratory tract infection   Sputum          1 month‒5 years     236               64               72                                47                            2360                *E. coli*, *K. pneumoniae*                                                                                                   Double disk synergy test                   CLSI, date NS
  Kim et al., 2017[@R52]                 Republic of Korea     Jan 2010--Jun 2015     Cohort            5 years 5 months   Hospital               Bacteraemia                         Blood           ≤ 17 years          185               49               93                                35                            185                 *E. coli*, *K. pneumoniae*                                                                                                   Double disk synergy test                   NCCLS, 2001
  Mandal et al., 2017[@R53]              India                 Two consecutive year   Cohort            2 years            Community              Diarrhoea                           Stool           0--60 months        633               72               119                               38                            633                 *E. coli*                                                                                                                    Modified Kirby-Bauer disk diffusion        CLSI, date NS
  Nisha et al., 2017[@R54]               India                 Nov 2012--Mar 2016     Cohort            4 years 5 months   Community              Urinary tract infection             Urine           3 months‒18 years   523               196              327                               38                            523                 *E. coli*                                                                                                                    Kirby-Bauer disk diffusion                 CLSI, 2010
  Tsai et al., 2017[@R55]                Taiwan, China         2010--2014             Observational     5 years            Hospital               Bacteraemia                         Blood           \< 3 years          41                14               27                                34                            41                  *E. coli*                                                                                                                    NS                                         NS
  Bunjoungmanee et al., 2018[@R56]       Thailand              Jun 2016--May 2017     Case--control     1 year             Hospital & community   Urinary tract infection             Urine           1 month‒5 years     80                40               40                                23                            80                  *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, 2010
  Kitagawa et al., 2018[@R57]            Indonesia and Japan   Jan--Nov 2014          Case--control     1 year             Hospital & community   Urinary tract infection             Urine           0--15 years         94                37               13                                39                            94                  *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI, date NS
  Weerasinghe et al., 2018[@R58]         Sri Lanka             Jan--April 2011        Cohort            3 months           Hospital               Various                             Various         Neonates            50                18               8                                 36                            50                  *E. coli*, *K. pneumoniae*                                                                                                   Double disk diffusion                      CLSI & CDC, 2011

CDC: Centers for Disease Control and Prevention; CLSI: Clinical and Laboratory Standards Institute; ESBL: extended-spectrum β-lactamase-producing bacteria; NCCLS: National Committee for Clinical Laboratory Standards; NS: not specified.

^a^ Multiple species included *Klebsiella pneumonia*; *Escherichia coli*; *Pseudomonas* spp.; *Acinetobacter* spp.; *Enterobacter* spp.; and *Citrobacter* spp.

^b^ Studies with data only on isolates; the remaining studies included data on patients and isolates.

^c^ Neutrpoenia study.

^d^ Urinary tract infection study.

### Risk factors

The risk of infection with extended-spectrum β-lactamase-producing bacteria was significantly higher for patients whose medical history included intensive care unit admission (OR: 6.5; 95% CI: 3.04 to 13.73; *I^2^*: 65%; six studies), hospitalization (OR: 3.3; 95% CI: 1.95 to 5.57; *I^2^*: 80%; 11 studies) or surgery (OR: 2.3; 95% CI: 1.41 to 3.81; *I^2^*: 25%; six studies; [Table 2](#T2){ref-type="table"}).

###### Pooled risk of extended-spectrum β-lactamase-associated infection among children and young adults in South-East Asia and Western Pacific countries by medical history and co-morbid conditions, 2002--2018

  Subgroup                                                No. of studies   Total no. of patients   ESBL-positive, no.         ESBL-negative, no.   Pooled OR (95% CI)^a^   *I^2^*, %                               
  ------------------------------------------------------- ---------------- ----------------------- -------------------- ----- -------------------- ----------------------- ----------- --------------------------- ----
  **Received medical care in previous 3 months**                                                                                                                                                                   
  Recent intensive care unit stay                         6                1258                    124                  399                        65                      859         6.46 (3.04 to 13.73)        65
  Recent hospitalization                                  11               2936                    318                  727                        367                     2209        3.30 (1.95 to 5.57)         80
  Recent surgery                                          6                1178                    58                   433                        37                      745         2.32 (1.41 to 3.81)         8
  Pre-infection hospitalization                           3                223                     NA                   110                        NA                      113         11.42^b^ (−7.86 to 30.71)   99
  **Diagnosis of co-morbid or underlying conditions**                                                                                                                                                              
  Bacteraemia                                             6                958                     103                  222                        109                     736         5.30 (3.64 to 7.72)         38
  Lower respiratory tract infection                       4                837                     213                  395                        134                     442         5.01 (3.50 to 7.19)         79
  Recurrent urinary tract infection                       11               2149                    355                  808                        328                     1341        2.01 (1.67 to 2.43)         90
  Nosocomial infection                                    2                114                     40                   55                         21                      59          5.19 (2.23 to 12.07)        92
  Various diagnoses                                       7                1772                    229                  545                        339                     1227        2.68 (2.06 to 3.48)         79
  Sepsis                                                  10               970                     397                  550                        146                     420         4.61 (3.34 to 6.35)         80
  **Received antibiotics in the previous 3 months**                                                                                                                                                                
  Third-generation cephalosporin                          11               2318                    384                  777                        249                     1541        4.81 (2.25 to 10.27)        89
  Vancomycin                                              3                813                     69                   235                        79                      578         3.39 (2.21 to 5.20)         0
  Quinolone                                               5                1242                    105                  477                        55                      765         2.99 (1.04 to 8.63)         79
  Carbapenem                                              5                1156                    68                   405                        49                      751         2.85 (1.47 to 5.53)         42
  Aminoglycoside                                          7                1444                    151                  485                        235                     959         2.84 (1.21 to 6.65)         83
  Penicillin                                              9                1750                    380                  798                        249                     952         2.87 (1.10 to 7.47)         92
  **Received antibiotic prophylaxis**                     4                703                     84                   238                        132                     465         1.82 (1.16 to 2.86)         0
  **Received any antibiotic**                             13               2289                    340                  584                        457                     1705        3.58 (2.30 to 5.57)         60
  **Received appropriate empirical antibiotic therapy**   5                803                     102                  192                        463                     611         0.29 (0.11 to 0.79)         65
  **Exposed to invasive life support**                                                                                                                                                                             
  Total parenteral nutrition                              5                805                     216                  283                        350                     522         3.77 (1.35 to 10.56)        79
  Continuous positive airway pressure                     3                682                     148                  241                        303                     441         3.35 (0.54 to 20.61)        91
  Mechanical ventilation                                  6                1098                    137                  432                        271                     666         3.29 (1.03 to 10.53)        83
  Endotracheal intubation                                 8                1157                    187                  407                        347                     750         2.06 (1.22 to 3.49)         61
  Central venous catheter                                 9                957                     244                  352                        429                     605         1.69 (1.00 to 2.85)         41

CI: confidence interval; EBSL: extended-spectrum β-lactamase-producing bacteria; NA: not applicable; OR: odds ratio.

^a^ Mantel--Haenszel random-effects.

^b^ Pre-infection hospitalization is the time of hospitalization to the time while patients with confirmed infection with extended-spectrum β-lactamase-producing Enterobacteriaceaeis, expressed as mean difference in days between positive and negative patients (standard deviation).

The risk of infection was higher for patients with co-existing bacteraemia (OR: 5.3; 95% CI: 3.64 to 7.72; *I^2^*: 38%; six studies), nosocomial infections (OR: 5.2; 95% CI: 2.23 to 12.07; *I^2^*: 92%; two studies), lower respiratory tract infections (OR: 5.0; 95% CI: 13.50 to 7.19; *I^2^*: 79%; four studies), sepsis (OR: 4.6 95% CI: 3.34 to 6.35; *I^2^*: 80%; 10 studies) or recurrent urinary tract infections (OR: 2.0; 95% CI: 1.61 to 2.43; *I^2^*: 90%; 11 studies; [Table 2](#T2){ref-type="table"}).

Antibiotics associated with risk of infection included third-generation cephalosporins (OR: 4.8; 95% CI: 2.25 to 10.27; *I^2^*: 89; 11 studies), vancomycin (OR: 3.4; 95% CI: 2.21 to 5.20; *I^2^*: 0%; three studies) and quinolones (OR: 3.0; 95% CI: 1.04 to 8.63, *I^2^*: 79; five studies). Five studies reported that appropriate initiation of empirical antibiotics was protective, showing a pooled OR of infection of 0.29 (95% CI: 0.11 to 0.79; *I^2^*: 65%; five studies; [Table 2](#T2){ref-type="table"}).

Exposure to continuous positive airway pressure therapy was not significantly associated with a risk of infection (OR: 3.4; 95% CI: 0.54 to 20.61; three studies). Other types of invasive life support were a risk, however. The OR for total parenteral nutrition was 3.8 (95% CI: 1.35 to 10.56; five studies). For mechanical ventilation the OR was 3.3 (95% CI: 1.03 to 10.53; six studies) and for endotracheal intubation 2.1 (95% CI: 1.22 to 3.49; eight studies). Central venous catheterization had an OR of 1.7 (95% CI: 1.00 to 2.85; nine studies; [Table 2](#T2){ref-type="table"}).

### Treatment outcomes

Most specimens from patients with extended-spectrum β-lactamase-producing bacterial infection showed resistance to multiple antibiotics. The risk of antibiotic resistance was highest for extended-spectrum β-lactamase-positive patients treated with cephalosporins (OR: 70.5; 95% CI: 43.25 to 115.02; *I^2^*: 83%; 25 studies) and lowest with cotrimoxazole (OR: 1.8; 95% CI: 1.35 to 2.47; *I^2^*: 43%; 15 studies). The ORs for resistance to tetracyclines and nitrofurantoin were not statistically significant ([Table 3](#T3){ref-type="table"}).

###### Pooled risk of antibiotic resistance to extended-spectrum β-lactamase-producing bacteria in specimens from children and young adults in South-East Asia and Western Pacific countries by antibiotic class, 2002--2018

  Antibiotic class   No. of studies   Total no. of patients   ESBL-positive   ESBL-negative   Pooled OR (95% CI)^a^   *I^2^*, %                             
  ------------------ ---------------- ----------------------- --------------- --------------- ----------------------- ----------- ------------------------- ----
  Cephalosporins     25               3444                    1339            1483            632                     1961        70.50 (43.25 to 115.02)   83
  Monobactams        8                879                     274             412             63                      467         41.16 (14.05 to 120.55)   58
  Penicillins        24               3148                    1160            1304            1091                    1844        19.41 (8.67 to 43.46)     86
  Aminoglyclosides   25               3449                    495             1452            276                     1997        5.71 (3.42 to 9.54)       74
  Combinations^b^    22               2993                    706             1141            739                     1852        4.37 (1.95 to 9.82)       91
  Carbapenems        22               2940                    79              1244            64                      1696        3.99 (1.68 to 9.48)       0
  Fluoroquinolones   25               3351                    627             1439            607                     1912        3.33 (2.14 to 5.17)       78
  Cotrimoxazole      15               2346                    547             868             755                     1478        1.82 (1.35 to 2.47)       43
  Tetracyclines      7                1447                    355             619             357                     828         1.58 (0.76 to 3.30)       81
  Nitrofurantoin     3                1039                    58              423             90                      6           0.97 (0.64 to 1.46)       14

CI: confidence interval; EBSL: extended-spectrum β-lactamase-producing bacteria; OR: odds ratio.

^a^ Mantel--Haenszel random-effects.

^b^ Combinations: Ampicillin + sulbactam; ticarcillin + clavulanic acid; amoxicillin + clavulanate; cefoperazone + sulbactam; piperacillin + tazobactam; ceftazidime+ clavulanic acid.

The duration of fever was 0.61 days longer in patients with extended-spectrum β-lactamase-producing bacteria than patients without (95% CI: 0.18 to 0.72; *I^2^*: 92%; seven studies; [Fig. 2](#F2){ref-type="fig"}). Pooling five studies we found that persistent bacteraemia was four times higher in patients positive for extended-spectrum β-lactamase-producing bacteria (95% CI: 2.66 to 6.14; *I^2^*: 0%; [Fig. 3](#F3){ref-type="fig"}). Results from eight studies showed that the mean difference in length of hospital stay was 25.9 days (95% CI: 12.81 to 38.89; *I^2^*: 100%) for patients with extended-spectrum β-lactamase-associated infection than those without such infection ([Fig. 4](#F4){ref-type="fig"}). Subgroup analysis showed that the mean length of hospital stay associated with infection was 29 days longer for patients who had recently been admitted to an intensive care unit care than the patients not receiving this care. Similar results were seen for invasive life support; the mean length of stay after central venous catheterization was 33 days longer than without catheterization.^59^
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Eleven studies reported a pooled number of 188 deaths among 565 patients with extended-spectrum β-lactamase-associated infections compared with 86 deaths in 745 patients without these infections (OR: 3.2; 95% CI: 1.82 to 5.80; *I^2^:* 49%; [Fig. 5](#F5){ref-type="fig"}). When analysed by subgroups, the risk of death for patients who had previously been admitted to the intensive care unit or exposed to central venous catheterization were not significant. However, the risk of death was higher among patients with sepsis (OR: 4.9 95% CI: 2.11 to 11.39; *I^2^*: 38%) than those without sepsis (OR: 2.3 95% CI: 1.19 to 4.26; *I^2^*: 35%;).^59^
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We also looked at the ORs for neonates and non-neonates but the differences not statistically significant between these groups.^59^

### Validity tests

None of the factors we analysed by meta-regression were contributors to between-study heterogeneity. In the Newcastle-Ottawa analysis of risk of bias, we found that 60% (24 out of 40) of studies scored high on risk of bias and 40% were low risk ([Table 4](#T4){ref-type="table"}; [Table 5](#T5){ref-type="table"}). Only four studies had clear statements about comparability and 10 about representativeness. The results from Egger's regression test revealed that publication bias was significant (*P* \< 0.001). Sensitivity analysis excluding small studies with samples less than 10 revealed that the funnel plots were consistently asymmetric (*P* \< 0.001; available from the corresponding author). The sensitivity analysis showed that the data were not consistent with from the overall estimated ORs and similar trends were observed. This evaluation showed that a more restricted analysis of the data did not affect the magnitude, direction and the overall summary estimate.

###### Risk of bias in case--control and cross-sectional studies included in the meta-analysis of extended-spectrum β-lactamase-associated infection among children and young adults in South-East Asia and Western Pacific countries, 2005--2018

  Author                                Selection       Comparability       Exposure   Total score^b^                  
  ------------------------------------- ----------- --- --------------- --- ---------- ---------------- --- --- -- --- ---
  Boo et al., 2005[@R22]                0           1   1               1              0                1   1      1   6
  Kuo et al., 2007[@R26]                0           1   1               0              0                1   1      1   5
  Gaurav et al., 2011[@R33]             0           1   1               0              0                1   1      1   5
  Minami et al., 2012[@R36]^,c^         1           0   0               0              0                1   1      1   4
  Fan et al. 2014[@R39]                 0           1   1               1              0                1   1      1   6
  Themphachana et al., 2014[@R40]^,c^   0           1   0               0              0                1   1      1   4
  Young et al., 2014[@R41]^,c^          1           1   0               1              0                1   1      0   5
  Zuo et al., 2014[@R42]^,c^            0           0   1               0              1                1   0      1   4
  Sharma et al., 2016[@R48]^,c^         0           1   0               1              0                1   1      1   5
  Tsai et al., 2017[@R55]               1           1   0               1              0                1   1      1   6
  Chen et al., 2017[@R50]               1           1   0               0              0                1   1      1   5
  Bunjoungmanee et al., 2018[@R56]      0           1   1               0              0                1   1      0   4
  Kitagawa et al., 2018[@R57]           0           1   1               0              0                1   1      0   4

^a^ Subjects in different outcome groups are comparable, based on the study design or analysis.

^b^ Maximum score: 8.

^c^ Cross-sectional study.

Notes: We applied the Newcastle--Ottawa scale to assess risk of bias in non-randomized studies.[@R14] Only studies scoring ≥ 5 and ≤ 8 were designated low risk of bias, ≥ 3 and ≤ 4 as moderate and ≤ 2 as high. We made Mantel-Haenszel radom-effects

###### Risk of bias in cohort studies included in the meta-analysis of extended-spectrum β-lactamase-associated infection among children and young adults in South-East Asia and Western Pacific countries, 2002--2018

  Author                             Selection       Comparability       Exposure   Total score^b^                  
  ---------------------------------- ----------- --- --------------- --- ---------- ---------------- --- --- -- --- ---
  Kim et al., 2002[@R20]             0           0   1               0              0                1   1      1   4
  Jain et al., 2003[@R21]            0           0   1               0              0                1   1      1   4
  Chiu et al., 2005[@R23]            1           0   1               0              0                1   1      1   5
  Huang et al., 2007[@R24]           0           0   1               0              0                1   1      1   4
  Jain & Mondal, 2007[@R25]          0           0   1               0              0                1   1      1   4
  Lee et al., 2007[@R27]             1           0   1               0              0                1   1      1   5
  Sehgal et al., 2007[@R28]          0           0   1               0              0                1   1      1   4
  Bhattacharjee et al., 2008[@R29]   0           0   1               0              0                1   1      1   4
  Anandan et al., 2009[@R30]         0           0   1               0              0                1   1      1   4
  Kim et al., 2009[@R31]             0           0   1               0              0                1   1      1   4
  Shakil et al., 2010[@R32]          1           0   1               0              0                1   1      1   5
  Liu et al., 2011[@R34]             0           0   1               0              0                1   1      1   4
  Wei et al., 2011[@R35]             0           0   1               0              0                1   1      1   4
  Zheng et al., 2012[@R37]           0           0   1               0              0                1   1      1   4
  Vijayakanthi et al., 2013[@R38]    0           0   1               0              0                1   1      1   5
  Themphachana et al., 2014[@R40]    0           0   1               0              0                1   1      1   4
  Duong et al., 2015[@R43]           0           0   1               0              0                1   1      1   4
  Han et al., 2015[@R17]^,c^         0           0   1               0              0                1   1      1   4
  Han et al., 2015[@R44]^,d^         0           0   1               0              0                1   1      1   4
  Nisha et al., 2015[@R45]           0           0   1               0              1                1   1      1   5
  Agarwal et al., 2016 [@R46]        0           0   1               0              0                1   1      1   4
  Amornchaicharoensuk, 2016[@R47]    0           0   1               0              1                1   1      1   5
  He et al., 2017[@R51]              1           0   1               0              0                1   1      1   5
  Kim et al., 2017[@R52]             1           0   1               0              0                1   1      1   5
  Mandal et al., 2017[@R53]          0           0   1               0              1                1   1      0   4
  Nisha et al., 2017[@R54]           0           0   1               0              0                1   1      1   4
  Tsai et al., 2017[@R55]            1           0   0               0              0                1   1      1   4
  Weerasinghe et al., 2018[@R58]     0           1   1               0              0                1   1      0   4

^a^ Subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled

^b^ Maximum score: 8.

^C^ Neutropoenia study

^d^ Urinary tract infection study.

Notes: We applied the Newcastle--Ottawa scale to assess risk of bias in non-randomized studies.[@R14] Only studies scoring ≥ 5 and ≤ 8 were designated low risk of bias, ≥ 3 and ≤ 4 as moderate and ≤ 2 as high.

Prevalence study
----------------

The overall pooled prevalence of extended-spectrum β-lactamase in the studies included the meta-analysis combined with surveillance reports was 25.3%. The pooled prevalence from the studies in the meta-analysis was 39% among the 31 studies conducted in hospital settings and 31% in the seven studies conducted in community settings (two studies were in both hospital and the community).

Using data from other sources, we mapped population surveillance data from a total of 21 countries and areas in the South-East Asia and the Western Pacific Regions ([Table 6](#T6){ref-type="table"}). The pooled data from all available surveillance resources that included adults and children showed that India had the highest pooled prevalence (90.0%) and Australia the lowest (3.6%; numerators and denominators unavailable). The pooled data specifically for children, where available from surveillance resources and published data, showed similar results ([Fig. 6](#F6){ref-type="fig"}).

###### Pooled prevalence of overall population of extended-spectrum β-lactamase-associated infection from available surveillance data in 20 South-East Asia and Western Pacific countries or areas

  Country or area                                        Data source^a^             Prevalence in children^b^ by data source               Prevalence in children and adults^c^ by data source   Pooled prevalence, %               
  ------------------------------------------------------ -------------------------- ------------------------------------------ ----------- ----------------------------------------------------- ---------------------- ----------- ------
  Australia                                              SENTRY, 1998--1999[@R60]   NA                                         NA                                                                660                    8 (1.2)     3.6
  SMART, 2011[@R61]                                      80                         2 (2.5)                                                80                                                    2 (2.5)                            
  CDDEP, 2011--2014[@R10]                                NA                         NA                                                     NR                                                    NR (4.5)                           
  AURA, 2015[@R62]                                       NA                         NA                                                     NR                                                    NR (6.0)                           
  Bhutan                                                 CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (29.5)   29.5
  Brunei Darussalam                                      CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (4.5)    4.5
  Cambodia                                               CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (49.5)   49.5
  China                                                  SENTRY, 1998--1999[@R61]   NA                                         NA                                                                247                    63 (25.5)   47.5
  CDDEP, 2011--2014[@R10]                                NA                         NA                                                     NR                                                    NR (69.5)                          
  China, Hong Kong Special Administrative Region         SENTRY, 1998--1999[@R61]   NA                                         NA                                                                324                    43 (13.3)   13.3
  Taiwan, China                                          SENTRY, 1998--1999[@R61]   NA                                         NA                                                                139                    11 (7.9)    7.9
  India                                                  CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (90.0)   90.0
  Japan                                                  SENTRY, 1998--1999[@R61]   NA                                         NA                                                                272                    18 (6.6)    10.6
  CDDEP, 2011--2014[@R10]                                NA                         NA                                                     NR                                                    NR (14.5)                          
  Malaysia                                               CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (14.5)   14.5
  Federated States of Micronesia (Federated States of)   CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (69.5)   69.5
  Myanmar                                                CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (69.5)   69.5
  Nepal                                                  CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (29.5)   29.5
  New Zealand                                            CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (4.5)    3.7
  ESR, 2016[@R63]                                        NR                         NR (2.8)                                               NR                                                    NR (2.8)                           
  Papua New Guinea                                       CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (29.5)   29.5
  Philippines                                            SENTRY, 1998--1999[@R61]   NA                                         NA                                                                298                    58 (19.5)   24.5
  CDDEP, 2011--2014[@R10]                                NA                         NA                                                     NR                                                    NR (29.5)                          
  Republic of Korea                                      CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (29.5)   29.5
  Singapore                                              SENTRY, 1998--1999[@R61]   NA                                         NA                                                                153                    31 (20.3)   20.3
  Thailand                                               CDDEP, 2011--2014[@R10]    NA                                         NA                                                                NR                     NR (29.5)   29.5
  Viet Nam                                               SMART, 2011[@R61]          38                                         15 (39.5)                                                         38                     15 (39.5)   54.5
  CDDEP, 2011--2014[@R10]                                NA                         NA                                                     NR                                                    NR (69.5)                          

EBSL: extended-spectrum β-lactamase; NA: not applicable; NR: not reported.

^a^ Data sources: AURA: Antimicrobial Use and Resistance in Australia Surveillance System; CDDEP: Center for Disease Dynamics, Economics & Policy; ESR: Institute of Environmental Science and Research Surveillance System in New Zealand; SENTRY: Antimicrobial Surveillance Program by JMI Laboratories; SMART: Study for Monitoring Antimicrobial Resistance Trends.

^b^ Ages 0--21 years.

^c^ Ages not specified.

Notes: We searched the published and grey literature for surveillance data from all Member States and areas in the World Health Organization South-East Asia and Western Pacific Regions. No data were available for: Bangladesh, Cook Islands, Democratic People\'s Republic of Korea, Fiji, Indonesia, Kiribati, Lao People\'s Democratic Republic, Maldives, Marshall Islands, Mongolia, Nauru, Niue, Palau, Samoa, Solomon Islands, Timor-Leste, Tonga, Tuvalu and Vanuatu.
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Discussion
==========

This study revealed that the average combined prevalence of infection with extended-spectrum β-lactamase-producing bacteria among children in South-East Asia and the Western Pacific is high. Risk factors for infection included recent intensive care unit admission, hospitalization, surgery or antibiotic exposure, and co-existing bacteraemia, nosocomial infections, lower respiratory tract infections, sepsis or recurrent urinary tract infections. Infection was associated with higher mortality, higher morbidity and longer hospitalization.

The prevalence of infection we found in South-East Asia and the Western Pacific countries are similar to those reported from other surveillance systems worldwide,[@R64]although many locations do not report data for children. A review of worldwide trends in extended-spectrum β-lactamase-associated infection reported higher prevalence in Asia, Latin America and the Middle East (from 28 to 40%) compared with other, higher-income areas (from 8 to 12%).[@R64]

As many of the studies we found were hospital-based our results support the need for resources and policies for control of nosocomial infection. A recently published modelling study showed that antibiotic use in hospital is a major driver for antimicrobial resistance in human infection compared with animal and environmental antibiotic exposures.[@R65] Although infection control and hygiene may be sub-optimal in the countries we studied, infection control is easier to manage within health-care institutions than in other unstructured systems such as animal husbandry and the environment. Without proper control of antimicrobial resistance in hospitals, patients can disseminate antibiotic residues and resistance genes to the community and environment. This still highlights the importance of hospital-based stewardship for controlling antibiotic use and how this stewardship can reduce the risk of developing multidrug resistant organisms.[@R66] At the same time, the rising community prevalence of extended-spectrum β-lactamase-associated infection provides evidence for expanding prevention to other settings.[@R3]

Our meta-analysis showed that recent medical care, including intensive care unit stays, hospitalization, surgery and antibiotic therapy, was associated with increased risk of infection. These results suggest that children may acquire such infections during health care, especially when undergoing invasive procedures. Specifically, children who had exposure to third-generation cephalosporins, carbapenems and fluoroquinolones had three to four times greater risk for extended-spectrum β-lactamase-associated infection, which is similar to previous reports.[@R26]^,^[@R67]^--^[@R71] As these antibiotics are primarily used for treating severe infections, their use may be a marker for disease severity rather than a direct contributor to developing resistance. Nevertheless, if excessive fluoroquinolone use does contribute to emergence of resistant bacteria this adds another reason to avoid the unnecessary use of these broad-spectrum antibiotics in children.

Coexisting illnesses, including bacteraemia, nosocomial infection, lower respiratory tract infections, sepsis and recurrent urinary tract infections, were associated with increased risk of infection. These co-morbidities could be risk factors for use of invasive treatments such as a central venous catheterization, mechanical ventilation, intravenous nutrition or increased risk of interactions with health-care settings. In a two-centre case--control study of risk factors for infection with extended-spectrum β-lactamase-producers in children, multivariable analysis identified sepsis and neurological illnesses as potential risk factors, which supports our findings.[@R72] Previously published studies among both young adults and children found that prolonged hospital stay or prolonged use of invasive medical devices were associated with infection by, or being colonized with, extended-spectrum β-lactamase-producing bacteria,[@R26]^,^[@R69]^,^[@R71] which is consistent with our findings.

Recent surgery and antibiotic prophylaxis were associated with extended-spectrum β-lactamase infection in our study. Others have shown that surgical antibiotic prophylaxis increases the risk for antimicrobial resistance and acquisition of infection.[@R73] One study from Switzerland found that half of all surgical ward prescriptions (680 out of 1270) were inappropriate.[@R74] Antibiotic stewardship programmes have been shown to improve surgical antibiotic prophylaxis and treatment of surgical site infections.[@R75]

Our study found that initiation of appropriate empirical antibiotics was protective against extended-spectrum β-lactamase-associated infection, indicating the importance of thoughtful selection of antibiotics. The details of this finding warrant further study. The risk is especially high for critically ill patients requiring surgery or intensive care and who need antibiotics urgently before susceptibility has been established but who are also at increased risk for drug-resistant infections. Therefore, antibiotic stewardship programmes and guidelines in health-care facilities fill an important function. Furthermore, as studies in Asia have shown a high prevalence of easy access to unsupervised antibiotics within the community, more attention is needed to improving appropriate antibiotic use through training, education, policy and regulation outside of hospitals.[@R76]

Children infected with extended-spectrum β-lactamase-producers had significantly longer length of hospital stays (26 days) and required more intensive care unit days (29 days) than those without such infection. This leads to higher health-care costs,[@R77] in addition to the costs to society in terms of family and community pressures and lost productivity. At the same time, prolonging intensive care unit and hospital stays increases the risk of further acquisition and transmission of drug resistance.

Mortality and persistent bacteraemia were three to four times higher for patients infected with extended-spectrum β-lactamase-associated infections than those without. This adds to the economic and social burden of these infections. Based on our meta-regression, the study location, study design, patient's diagnosis, sex or intensive care unit stay did not influence mortality. This implies that worse outcomes may be directly attributable to the presence of extended-spectrum β-lactamase-associated infection. The severity of the diseases associated with these infections might also contribute to mortality risk, as the patients diagnosed with sepsis had higher risk of mortality than those without sepsis. However, we were unable to determine for each study whether other factors may have influenced outcomes because comprehensive information was not available.

One of the strengths of our study was the comprehensive data collection strategy, which provided a high sample size and study power. Second, two different tools were used to assess for bias, which, together with risk factor and outcomes sensitivity analysis, strengthened the study's validity and reliability. Third, we assessed previous antibiotic history with different antibiotic categories, providing a detailed insight into the link between antibiotic use and resistance. Fourth, we also conducted meta-regression to determine if other factors might have influenced treatment outcomes. This established association between patients' mortality, length of stay and extended-spectrum β-lactamase infections.

There were several limitations to this study. The distribution of studies between locations was not uniform. Of the 48 Member States and areas in the South-East Asia and the Western Pacific Regions, we were able to find and extract data for the meta-analysis from 12 countries. For prevalence estimates we added surveillance data from 10 other countries and areas but we found data on 0--21-years-olds for only three countries with available paediatric data, which might underestimate the real situation among children. Moreover, although we made subgroup analyses, most of the pooled prevalence from selected studies were from hospital settings. Most of the surveillance sources reported only prevalence, without denominators and numerators. Nevertheless, the study provides a rough indication of the extent of extended-spectrum β-lactamase-associated infection and highlights the need for establishment of surveillance systems in these Regions. We can expect that within large Regions, rates of infection are unlikely to be homogenous, particularly where there are large urban and rural disparities. Among 40 studies, only seven were community based. This might have underestimated antibiotic resistance in the community. With the rising concern for community-acquired infections and reports of increased rates of faecal colonization with extended-spectrum β-lactamase-producing bacteria in healthy children, risk factors might not only arise from hospital influences but also from community exposure and international travel.[@R78]^--^[@R80] Because of limited information in the articles, we are unable to determine whether longer hospitalization increased the risk of infections or vice versa. Both situations are likely and further studies are needed to clarify the associations.

Another limitation we faced was the lack of laboratory standardization for the identification of the extended-spectrum β-lactamase-producer phenotypes. Quality and standardization may vary between laboratories, although most followed Clinical and Laboratory Standards Institute guidelines. Sensitivity analyses found that use of different laboratory guidelines or test methods or the study year did not affect our results. All studies used phenotypic methods, as opposed to the gold standard through genotyping, with the majority using agar double-disk diffusion test, while a few studies used the Vitek® system (bioMérieux, Marcy l'Etoile, France). Thus, detection rates could be underestimated.

We hope this study will provide important information for policy-makers who need to allocate resources to improve surveillance, monitor treatment outcomes, improve infection control in intensive care unit and surgery wards and develop policies for the use of empirical and prophylactic antibiotics. Knowledge of resistance rates can guide treatment recommendations. Countries without established antibiotic stewardship programmes should prioritize these activities, along with public education programmes. With very high burden of neonatal sepsis 0.42 million (39%) of the total 1.09 million deaths related with sepsis in these Regions,[@R81] scaling up strategies to prevent infection and encourage appropriate treatment for this vulnerable group is needed. More studies are also needed to measure the impact of antimicrobial resistance in children.
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